Drug intelligence / Profile preview

GID-201

Development stage: Unknown
Lead developer: GID BIO
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

GID-201 is an autologous adipose-derived stromal vascular fraction (SVF) cell therapy developed by GID BIO for the treatment of osteoarthritis, particularly of the knee. The therapy is produced using a proprietary point-of-care system that isolates a concentrated population of regenerative cells—including mesenchymal stem cells, pericytes, and endothelial cells—from a patient's own adipose tissue. Once injected intra-articularly, these cells work through paracrine signaling to modulate the inflammatory environment, promote tissue homeostasis, and alleviate pain. It is specifically being evaluated for patients with Kellgren-Lawrence Grade II or III knee osteoarthritis to improve joint function and reduce chronic pain.

Other names: Autologous adipose-derived stromal vascular fractionSVF

Beyond the preview

Go deeper on GID-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GID-201.

Explore the full profile